secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2022-08-25T23:59:59+00:00
Accession:  0001193125-22-229043
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Quinn departs; interim CEO Kastenmayer named; restructuring cuts headcount 25%, prioritizes AGLE-177
--------------------------------------------------------------------------------

- CEO Anthony Quinn departed Aug 24, 2022 via mutual agreement; no disagreement; to serve as R&D Advisor then consultant through Sept 2023.
- James Kastenmayer (General Counsel) appointed Interim CEO; base salary raised to $588,000, target bonus set at 50%.
- Michael Hanley promoted to Chief Business Officer from Chief Commercial Officer.
- Restructuring reduces headcount ~25% YTD; transitions patients out of pegzilarginase extension studies in Arginase 1 Deficiency.
- Company prioritizes AGLE-177 development; expects cash runway extended into Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/0001193125-22-229043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312522229043/d253845d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-229043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer